The results increase “my confidence that this approach has merit,” Lauren Sansing says. More trials are on the way.

Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and ...

LOS ANGELES -- For patients with large vessel occlusion (LVO) strokes, researchers found ways to make adjunctive ...

Early findings suggest that IA tenecteplase after successful thrombectomy is safe and improves functional outcomes over standard care in anterior circulation LVO stroke.

The study did not include patients treated with intravenous clot-busting drugs or medications that reduce blood clotting, like heparin and anti-platelet drugs, during their endovascular procedures.

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with full-dose ...

Injecting tenecteplase into the artery after clot removal helps improve recovery in stroke survivors, leading to better functional outcomes.

Researchers at McMaster University have made a discovery in the field of hematology, providing an explanation for spontaneous ...

Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery ...

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and ...